Trial Profile
A Phase II Trial of Sitravatinib (MGCD516), a Multi-receptor Tyrosine Kinase Inhibitor, in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2022
Price :
$35
*
At a glance
- Drugs Sitravatinib (Primary) ; Pazopanib
- Indications Liposarcoma; Nerve sheath neoplasms; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 22 Dec 2022 Results assessing efficacy and safety of Sitravatinib for the treatment of well-differentiated/dedifferentiated liposarcoma, published in the Clinical Cancer Research.
- 04 Apr 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2023.
- 04 Apr 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Jan 2023.